Fachthema

Multiple myeloma

Clinical activity seen with anti-BCMA CAR T-cell therapy

Jatros Digital, 28.11.2017
Hämatologie | Onkologie

James N. Kochenderfer, MD, National Cancer Institute, presents the updated results from a multicenter study of bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

zurück zum ASH Newsroom 2017